WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Credit Rating
Revision of Credit Rating by CARE Ratings Limited (CARE Ratings)07-06-2023
07-06-2023
Wockhardt posts net loss of Rs 237 crore in Q4 FY 23
The Q4 net loss was less than the Rs 311-crore loss in the same quarter of FY22, but more than the sequential loss of -Rs 102 crore, in the previous quarter27-05-2023
WOCKHARDT LTD. - 532300 - Report On Related Party Transactions For Half Year Ended March 31, 2023.
In compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Statement of related party transactions in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November, 2021 for the half year ended 31st March, 2023.26-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Wockhardt Ltd.
Pharmaceuticals company Wockhardt announced Q4FY23 & FY23 results: Q4FY23: The Company recorded a Revenue of Rs 710 crore in Q4FY23 vs Rs 666 crore in Q4FY22, up 7% EBITDA for Q4FY23 is Rs 47 crore as compared to Rs (22) crore in Q4FY22 registering a substantial growth of 314% UK Business stood at Rs 242 crore in Q4FY23 compared to Rs 223 crore in Q3FY23 registering a growth of 8%. UK Business contributed about 36% of Global Revenue. India Business stood at Rs 125 crore in Q4FY23. India's Business contributed 19% of the Global Revenue. Emerging Markets Business of the Company stood at Rs 173 crore in Q4FY23 compared to Rs 148 crore in Q3FY23 registering a growth of 16%. Emerging Markets Business contributed about 25% of the Global Revenue. Irish Business stood at Rs 44 crore in Q4FY23 compared to Rs 40 crore in Q3FY23 showing a growth of 10%. US Business stood at Rs 50 crore in Q4FY23. US Business contributed 7% of the Global Revenue. FY23: UK Business stood at Rs 887 crore in FY23. UK Business contributed about 33% of Global Revenue. India's Business stood at Rs 609 crore in FY23. India's Business contributed 23% of the Global Revenue. Emerging Markets Business of the Company stood at Rs 555 crore in FY23. Emerging Markets Business contributed about 21% of the Global Revenue. Irish Business stood at Rs 158 crore in FY23 compared to Rs 153 crore in FY22, up 4% US Business stood at Rs 303 crore in FY23. US Business contributed 11% of the Global Revenue. Result PDF26-05-2023
WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release on the Audited Financial Results (Standalone and Consolidated) for the quarter and the Financial Year ended March 31, 2023.26-05-2023
WOCKHARDT LTD. - 532300 - Outcome Of The Board Meeting
Pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); audited Financial Results of the Company as on March 31, 2023 are enclosed.26-05-2023
WOCKHARDT LTD. - 532300 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); outcome of the Board meeting held today i.e. 26th May, 2023 is enclosed.26-05-2023
WOCKHARDT LTD. - 532300 - Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
This is to inform you that the Company has received a Settlement Order dated 22nd May 2023 from the Securities and Exchange Board of India in the matter of SEBI Show Cause Notice dated September 15, 2022 in the matter of non-disclosure of interim outcome of USFDA inspection in the year 2013. Vide the Settlement Order the charges contained in the said Show Cause Notice against the Company and its Directors viz. Dr. Habil Khorakiwala, Dr. Murtaza Khorakiwala and Dr. Huzaifa Khorakiwala have been disposed of without admission or denial of findings of fact and conclusions of law contained in the Show Cause Notice.23-05-2023